Key result
Advanced radiotherapy improves efficacy and safety but cardiotoxicity remains a significant late risk requiring mitigation.
Why the study?
Recent advances across radiotherapy practice, technology, and translational science required synthesis, with particular attention to radiation-induced cardiotoxicity as a key survivorship challenge.
Design
Narrative review
Requires long-term cardiac surveillance in cancer survivors; extends priority for cardiotoxicity mitigation research.
Radiotherapy transformed in 2015–2025, moving from incremental change to biologically informed, image-guided and increasingly automated care. This narrative review, informed by a comprehensive literature search of major databases (2015–2025), synthesises advances across clinical practice, technology, and translational science, with particular attention to radiation-induced cardiotoxicity as a key survivorship challenge. Randomised evidence established hypofractionation and stereotactic body radiotherapy as standards in selected breast, prostate and oligometastatic settings, improving efficiency without compromising control. Technological frontiers include MR-guided online adaptive radiotherapy for real-time plan modification, global expansion of proton therapy for paediatric indications and some adults, emerging biologically-guided radiotherapy (BgRT) platforms, expanding applications of radiopharmaceutical therapy (RPT), and early human feasibility of ultra-high dose-rate FLASH that may widen the therapeutic window. Artificial intelligence streamlines auto-segmentation, planning and quality assurance, while radiogenomics, radiomics and immuno-radiotherapy combinations advance personalisation. Amid these gains, late cardiovascular effects demand urgent focus: radiation-induced cardiotoxicity spans coronary, myocardial, valvular and conduction injury, with risk linked to dose-volume exposure and systemic co-therapies. Mitigation integrates deep-inspiration breath-hold, motion management, cardiac substructure contouring, proton techniques and biomarker-informed risk stratification. Persistent global access disparities, workforce shortages, and cost-effectiveness challenges highlight the need for pragmatic adoption of efficient regimens, equitable infrastructure investment, and supportive policy frameworks including AI-enabled remote planning and cloud-based quality assurance. This review synthesises advances, appraises cardiotoxicity evidence and countermeasures, and prioritises: integrate multi-omic biomarkers with adaptive, AI-enabled delivery; translate FLASH rigorously; build long-term cardio-oncology data; and implement policies extending modern radiotherapy beyond high-income settings. Radiotherapy is set to become more precise, personalised and equitable.
No takes yet. Share an insight, caveat, or question.
OİSAKEDE et al. (2026) studied this question. Advances in radiotherapy, including hypofractionation and proton therapy, improve efficacy and safety but radiation-induced cardiotoxicity remains a significant late risk requiring mitigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: